Toward Ultrasound Molecular Imaging With Phase-Change Contrast Agents: An In Vitro Proof of Principle

Ultrasound in Medicine and Biology

Volumn 39, Issue 5, 2013, Pages 893-902

  Sheeran, Paul S ^a   Streeter, Jason E ^a   Mullin, Lee B ^a   Matsunaga, Terry O ^b   Dayton, Paul A ^a  

^a USA and North Carolina State University   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Acoustic droplet vaporization; Contrast agent; Molecular imaging; Perfluorocarbon droplet; Phase change

Indexed keywords

BUBBLES (IN FLUIDS); DROPS; IMAGING TECHNIQUES; NANOTECHNOLOGY; PHASE TRANSITIONS; ULTRASONICS;

ACOUSTIC DROPLET VAPORIZATION; CONTRAST AGENT; MICROBUBBLE CONTRAST AGENTS; PERFLUOROCARBONS; PHASE CHANGES; PROOF OF PRINCIPLES; ULTRASOUND MOLECULAR IMAGING; VOLUMETRIC EXPANSION;

MOLECULAR IMAGING;

CONTRAST MEDIUM; FLUOROCARBON;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; MICROBUBBLE; MOLECULAR IMAGING; NANOIMAGING; PHASE CHANGE CONTRAST AGENT; PHASE TRANSITION; PRIORITY JOURNAL; TARGET CELL; ULTRASOUND; VAPORIZATION;

CELLS, CULTURED; CONTRAST MEDIA; ENDOTHELIAL CELLS; FEMALE; FLUOROCARBONS; HUMANS; MOLECULAR IMAGING; PILOT PROJECTS; ULTRASONOGRAPHY;

EID: 84875812488     PISSN: 03015629     EISSN: 1879291X     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2012.11.017     Document Type: Article

References (44)

1. Behan M., O'Connell D., Mattrey R., Carney D. Perfluorooctylbromide as a contrast agent for CT and sonography: Preliminary clinical results. Am J Roentgenol 1993, 160:399-405.
2. Chomas J.E., Dayton P., May D., Ferrara K. Threshold of fragmentation for ultrasonic contrast agents. J Biomed Opt 2001, 6:141-150.
3. Dayton P.A., Morgan K.E., Klibanov A.L., Brandenburger G.H., Ferrara K.W. Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control 1999, 46:220-232.
4. 3-expressing cells. Mol Imaging 2004, 3:125-134.
5. Deshpande N., Needles A., Willmann J.K. Molecular ultrasound imaging: current status and future directions. Clin Radiol 2009, 65:567-581.
6. Evans D.R., Parsons D.F., Craig V.S. Physical properties of phase-change emulsions. Langmuir 2006, 22:9538-9545.
7. Fabiilli M.L., Haworth K.J., Fakhri N.H., Kripfgans O.D., Carson P.L., Fowlkes J.B. The role of inertial cavitation in acoustic droplet vaporization. IEEE Trans Ultrason Ferroelectr Freq Control 2009, 56:1006-1017.
8. Feingold S., Gessner R., Guracar I.M., Dayton P.A. Quantitative volumetric perfusion mapping of the microvasculature using contrast ultrasound. Invest Radiol 2010, 45:669-674.
9. Gessner R., Dayton P.A. Advances in molecular imaging with ultrasound. Mol Imaging 2010, 9:117-127.
10. Giesecke T., Hynynen K. Ultrasound-mediated cavitation thresholds of liquid perfluorocarbon droplets in vitro. Ultrasound Med Biol 2003, 29:1359-1365.
11. Hall C.S., Lanza G.M., Rose J.H., Kaufmann R.J., Fuhrhop R.W., Handley S.H., Waters K.R., Miller J.G., Wickline S.A. Experimental determination of phase velocity of perfluorocarbons: applications to targeted contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control 2000, 47:75-84.
12. Hernot S., Klibanov A.L. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1153-1166.
13. Klibanov A.L. Microbubble contrast agents: Targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol 2006, 41:354-362.
14. Klibanov A.L., Rychak J.J., Yang W.C., Alikhani S., Li B., Acton S., Lindner J.R., Ley K., Kaul S. Targeted ultrasound contrast agent for molecular imaging of inflammation in high-shear flow. Contrast Media Mol Imaging 2006, 1:259-266.
15. Kripfgans O.D., Fowlkes J.B., Miller D.L., Eldevik O.P., Carson P.L. Acoustic droplet vaporization for therapeutic and diagnostic applications. Ultrasound Med Biol 2000, 26:1177-1189.
16. Kripfgans O.D., Fowlkes J.B., Woydt M., Eldevik O.P., Carson P.L. In vivo droplet vaporization for occlusion therapy and phase aberration correction. IEEE Trans Ultrason Ferroelectr Freq Control 2002, 49:726-738.
17. Lanza G., Winter P., Caruthers S., Hughes M.S., Hu G., Schmieder A.H., Wickline S.A. Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis 2010, 13:189-202.
18. Leong-Poi H., Christiansen J., Klibanov A.L., Kaul S., Lindner J.R. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation 2003, 107:455-460.
19. Lindner J.R., Song J., Xu F., Klibanov A.L., Singbartl K., Ley K., Kaul S. Noninvasive ultrasound imaging of inflammation using microbubbles targeted to activated leukocytes. Circulation 2000, 102:2745-2750.
20. Marsh J.N., Hall C.S., Scott M.J., Fuhrhop R.W., Gaffney P.J., Wickline S.A., Lanza G.M. Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. IEEE Trans Ultrason Ferroelectr Freq Control 2002, 49:29-38.
21. Martz T.M., Sheeran P.S., Bardin D., Lee A.P., Dayton P.A. Precision manufacture of phase-change perfluorocarbon droplets using microfluidics. Ultrasound Med Biol 2011, 37:1952-1957.
22. Mattrey R.F. Perfluorooctylbromide: A new contrast agent for CT, sonography, and MR imaging. Am J Roentgenol 1989, 152:247-252.
23. Mulder W.J., Strijkers G.J., van Tilborg G.A., Griffioen A.W., Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed 2006, 19:142-164.
24. Mullin L., Gessner R., Kwan J., Kaya M., Borden M.A., Dayton P.A. Effect of anesthesia carrier gas on in vivo circulation times of ultrasound microbubble contrast agents in rats. Contrast Media Mol Imaging 2011, 6:126-131.
25. Postema M., Marmottant P., Lancee C.T., Hilgenfeldt S., de Jong N. Ultrasound-induced microbubble coalescence. Ultrasound Med Biol 2004, 30:1337-1344.
26. Qin S., Caskey C.F., Ferrara K.W. Ultrasound contrast microbubbles in imaging and therapy: Physical principles and engineering. Phys Med Biol 2009, 54:R27-R57.
27. Contrast media in ultrasonography: Basic principles and clinical applications 2005, Springer, New York. E. Quaia (Ed.).
28. Rapoport N.Y., Kennedy A.M., Shea J.E., Scaife C.L., Nam K.H. Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release 2009, 138:268-276.
29. Reznik N., Williams R., Burns P.N. Investigation of vaporized submicron perfluorocarbon droplets as an ultrasound contrast agent. Ultrasound Med Biol. 2011, 37:1271-1279.
30. Reznik N., Seo M., Williams R., Bolewska-Pedyczak E., Lee M., Matsuura N., Gariepy J., Foster F.S., Burns P.N. Optical studies of vaporization and stability of fluorescently labelled perfluorocarbon droplets. Phys Med Biol. 2012, 57:7205-7217.
31. Sassaroli E., Hynynen K. Resonance frequency of microbubbles in small blood vessels: A numerical study. Phys Med Biol 2005, 50:5293.
32. Sheeran P.S., Wong V.P., Luois S., McFarland R.J., Ross W.D., Feingold S., Matsunaga T.O., Dayton P.A. Decafluorobutane as a phase-change contrast agent for low-energy extravascular ultrasonic imaging. Ultrasound Med Biol 2011, 37:1518-1530.
33. Sheeran P.S., Luois S., Dayton P.A., Matsunaga T.O. Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound. Langmuir 2011, 27:10412-10420.
34. Sheeran P.S., Dayton P.A. Phase-change contrast agents for imaging and therapy. Curr Pharm Des 2012, 18:2152-2165.
35. Sheeran P.S., Luois S., Mullin L., Matsunaga T.O., Dayton P.A. Design of ultrasonically-activatable nanoparticles using low boiling point perfluorocarbons. Biomaterials 2012, 33:3262-3269.
36. Staub D., Schinkel A.F.L., Coll B., Coli S., van der Steen A.F., Reed J.D., Krueger C., Thomenius K.E., Adam D., Sijbrands E.J., ten Cate F.J., Feinstein S.B. Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaques. J Am Coll Cardiol Img 2010, 3:761-771.
37. Streeter J.E., Gessner R., Miles I., Dayton P.A. Improving sensitivity in ultrasound molecular imaging by tailoring contrast agent size distribution: in vivo studies. Mol Imaging 2010, 9:87-95.
38. Streeter J.E., Gessner R.C., Tsuruta J., Feingold S., Dayton P.A. Assessment of molecular imaging of angiogenesis with three-dimensional ultrasonography. Mol Imaging 2011, 10:460-468.
39. Stride E.P., Coussios C.C. Cavitation and contrast: The use of bubbles in ultrasound imaging and therapy. Proc Inst Mech Eng H 2010, 224:171-191.
40. Thijssen J.M., Weijers G., de Korte C.L. Objective performance testing and quality assurance of medical ultrasound equipment. Ultrasound Med Biol 2007, 33:460-471.
41. Voigt J.U. Ultrasound molecular imaging. Methods 2009, 48:92-97.
42. Wang C.H., Huang Y.F., Yeh C.K. Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging. Langmuir 2011, 27:6971-6976.
43. Wang C.H., Kang S.T., Lee Y.H., Luo Y.L., Huang Y.F., Yeh C.K. Aptamer-conjugated and drug-loaded acoustic droplets for ultrasound theranosis. Biomaterials 2011, 33:1939-1947.
44. Zhang P., Porter T. An in vitro study of a phase-shift nanoemulsion: A potential nucleation agent for bubble-enhanced HIFU tumor ablation. Ultrasound Med Biol 2010, 36:1856-1866.